IDP Pharma has closed a 1,4M€ seed investment round, following a pre-seed round of 0,1M€ (June 2015), which adds up to the ca 0,6M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ).
The company will allocate the capital to advance the preclinical development of its prioritized product – a first in class drug for multiple mieloma treatment, to set up new discovery programs, and to continue developing its technological platform.
Source: IDP Pharma
cloud technology axon
tuTECHÔ, empresa social que lucha contra el sinhogarismo en España, ...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory